|
Gene: PRELID1 |
Gene summary for PRELID1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PRELID1 | Gene ID | 27166 |
Gene name | PRELI domain containing 1 | |
Gene Alias | CGI-106 | |
Cytomap | 5q35.3 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q9Y255 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27166 | PRELID1 | GSM4909281 | Human | Breast | IDC | 9.70e-05 | -2.05e-01 | 0.21 |
27166 | PRELID1 | GSM4909285 | Human | Breast | IDC | 2.17e-04 | 2.54e-02 | 0.21 |
27166 | PRELID1 | GSM4909286 | Human | Breast | IDC | 1.04e-23 | -4.97e-01 | 0.1081 |
27166 | PRELID1 | GSM4909293 | Human | Breast | IDC | 3.82e-13 | -2.20e-01 | 0.1581 |
27166 | PRELID1 | GSM4909296 | Human | Breast | IDC | 2.31e-13 | -4.17e-01 | 0.1524 |
27166 | PRELID1 | GSM4909297 | Human | Breast | IDC | 5.74e-24 | -5.27e-01 | 0.1517 |
27166 | PRELID1 | GSM4909298 | Human | Breast | IDC | 5.27e-04 | 7.77e-02 | 0.1551 |
27166 | PRELID1 | GSM4909308 | Human | Breast | IDC | 6.15e-06 | 8.85e-02 | 0.158 |
27166 | PRELID1 | GSM4909311 | Human | Breast | IDC | 3.09e-42 | -5.16e-01 | 0.1534 |
27166 | PRELID1 | GSM4909312 | Human | Breast | IDC | 3.51e-09 | -2.26e-01 | 0.1552 |
27166 | PRELID1 | GSM4909317 | Human | Breast | IDC | 3.50e-02 | -9.36e-02 | 0.1355 |
27166 | PRELID1 | GSM4909319 | Human | Breast | IDC | 1.55e-52 | -3.95e-01 | 0.1563 |
27166 | PRELID1 | GSM4909321 | Human | Breast | IDC | 5.01e-10 | -7.32e-02 | 0.1559 |
27166 | PRELID1 | ctrl6 | Human | Breast | Precancer | 5.50e-03 | -3.97e-01 | -0.0061 |
27166 | PRELID1 | brca1 | Human | Breast | Precancer | 4.47e-30 | 5.94e-01 | -0.0338 |
27166 | PRELID1 | brca3 | Human | Breast | Precancer | 3.08e-02 | 2.33e-01 | -0.0263 |
27166 | PRELID1 | M1 | Human | Breast | IDC | 8.37e-03 | -2.33e-01 | 0.1577 |
27166 | PRELID1 | NCCBC14 | Human | Breast | DCIS | 8.62e-06 | -2.67e-01 | 0.2021 |
27166 | PRELID1 | NCCBC5 | Human | Breast | DCIS | 5.49e-12 | -1.44e-01 | 0.2046 |
27166 | PRELID1 | P1 | Human | Breast | IDC | 3.63e-29 | -7.52e-01 | 0.1527 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004346710 | Prostate | BPH | regulation of generation of precursor metabolites and energy | 44/3107 | 130/18723 | 1.16e-06 | 2.07e-05 | 44 |
GO:000863716 | Prostate | BPH | apoptotic mitochondrial changes | 35/3107 | 107/18723 | 3.17e-05 | 3.60e-04 | 35 |
GO:001063916 | Prostate | BPH | negative regulation of organelle organization | 87/3107 | 348/18723 | 3.56e-05 | 3.90e-04 | 87 |
GO:19021058 | Prostate | BPH | regulation of leukocyte differentiation | 71/3107 | 279/18723 | 9.94e-05 | 9.21e-04 | 71 |
GO:004211010 | Prostate | BPH | T cell activation | 111/3107 | 487/18723 | 2.11e-04 | 1.72e-03 | 111 |
GO:001082110 | Prostate | BPH | regulation of mitochondrion organization | 41/3107 | 144/18723 | 2.40e-04 | 1.92e-03 | 41 |
GO:000183610 | Prostate | BPH | release of cytochrome c from mitochondria | 21/3107 | 59/18723 | 3.20e-04 | 2.43e-03 | 21 |
GO:19031315 | Prostate | BPH | mononuclear cell differentiation | 98/3107 | 426/18723 | 3.43e-04 | 2.55e-03 | 98 |
GO:00518818 | Prostate | BPH | regulation of mitochondrial membrane potential | 24/3107 | 74/18723 | 6.06e-04 | 4.16e-03 | 24 |
GO:005086310 | Prostate | BPH | regulation of T cell activation | 76/3107 | 329/18723 | 1.32e-03 | 7.95e-03 | 76 |
GO:00300982 | Prostate | BPH | lymphocyte differentiation | 83/3107 | 374/18723 | 2.76e-03 | 1.46e-02 | 83 |
GO:00456193 | Prostate | BPH | regulation of lymphocyte differentiation | 43/3107 | 174/18723 | 3.84e-03 | 1.92e-02 | 43 |
GO:00302174 | Prostate | BPH | T cell differentiation | 58/3107 | 257/18723 | 7.66e-03 | 3.39e-02 | 58 |
GO:00455802 | Prostate | BPH | regulation of T cell differentiation | 36/3107 | 146/18723 | 7.96e-03 | 3.47e-02 | 36 |
GO:00109173 | Prostate | BPH | negative regulation of mitochondrial membrane potential | 6/3107 | 13/18723 | 1.24e-02 | 4.94e-02 | 6 |
GO:200123319 | Prostate | Tumor | regulation of apoptotic signaling pathway | 137/3246 | 356/18723 | 1.01e-21 | 1.25e-18 | 137 |
GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
GO:004533317 | Prostate | Tumor | cellular respiration | 93/3246 | 230/18723 | 8.89e-17 | 2.22e-14 | 93 |
GO:001598017 | Prostate | Tumor | energy derivation by oxidation of organic compounds | 116/3246 | 318/18723 | 1.54e-16 | 3.54e-14 | 116 |
GO:004586219 | Prostate | Tumor | positive regulation of proteolysis | 124/3246 | 372/18723 | 3.46e-14 | 4.31e-12 | 124 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRELID1 | SNV | Missense_Mutation | rs758980479 | c.514N>A | p.Glu172Lys | p.E172K | Q9Y255 | protein_coding | tolerated(0.25) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRELID1 | SNV | Missense_Mutation | c.197C>T | p.Ala66Val | p.A66V | Q9Y255 | protein_coding | deleterious(0.01) | possibly_damaging(0.733) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRELID1 | SNV | Missense_Mutation | c.610N>A | p.Ala204Thr | p.A204T | Q9Y255 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRELID1 | SNV | Missense_Mutation | c.436N>G | p.Phe146Val | p.F146V | Q9Y255 | protein_coding | deleterious(0) | possibly_damaging(0.781) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PRELID1 | SNV | Missense_Mutation | rs758358635 | c.383G>A | p.Arg128Gln | p.R128Q | Q9Y255 | protein_coding | tolerated(0.08) | probably_damaging(0.989) | TCGA-KR-A7K0-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PRELID1 | SNV | Missense_Mutation | novel | c.413G>C | p.Gly138Ala | p.G138A | Q9Y255 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-ZS-A9CE-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRELID1 | SNV | Missense_Mutation | c.125G>T | p.Arg42Leu | p.R42L | Q9Y255 | protein_coding | tolerated(0.07) | benign(0.396) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
PRELID1 | SNV | Missense_Mutation | novel | c.481G>T | p.Gly161Cys | p.G161C | Q9Y255 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PRELID1 | SNV | Missense_Mutation | c.594G>C | p.Glu198Asp | p.E198D | Q9Y255 | protein_coding | deleterious(0.03) | probably_damaging(0.935) | TCGA-34-5929-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRELID1 | SNV | Missense_Mutation | novel | c.380G>T | p.Arg127Leu | p.R127L | Q9Y255 | protein_coding | tolerated(0.1) | benign(0.049) | TCGA-CQ-6228-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |